Drugs / ASP1002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05719558 | Mar 2023 → Apr 2028 expected | cancer | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05719558 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT05719558 ↗ |